World Allergy Organ JWorld Allergy Organ JThe World Allergy Organization Journal1939-4551World Allergy Organization44066021939-4551-8-S1-A18210.1186/1939-4551-8-S1-A182Meeting AbstractSerum soluble fas ligand levels and peripheral blood lymphocyte subtypes in patients with drug induced maculopapular rashes, dress and viral exanthemasYaziciogluMehtap1TurgutBurhan1OzdemirPinar Gokmirza1Trakya University, Turkey20158420158Suppl 13rd WAO International Scientific Conference (WISC) 2014Publication of this supplement was funded by the World Allergy Organization.A182A182Copyright © 2015 Yazicioglu et al; licensee BioMed Central Ltd.2015Yazicioglu et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.6-9 December 20143rd WAO International Scientific Conference (WISC) 2014Rio de Janeiro, BrazilBackground

Fas/Fas ligand (FasL)-dependent apoptotic pathway was reported to be involved in the pathogenesis of drug induced maculopapular rashes (MPRs). In this study, we investigated serum soluble FasL level to discriminate drug-induced skin reactions from other clinically resembling skin diseases such as exanthematous viral infections. We also eveluated the role of T cells in various drug-induced diseases.

Methods

We analyzed 7 patients with drug induced MPRs (group I), 17 patients with viral exanthemas (group II), 6 paients with DRESS [grup III], and 15 healthy children with no history of adverse drug reactions. A complete blood count and immunophenotyping of peripheral blood lymphocytes were carried out, as well serum FasL levels were analyzed in group I-III (Human sFas-L ELISA kit, eBioscience, Vienna, Austria), within 2 days after the onset of the skin eruptions. Tests were repeated between days 3-5 and days 6-10. In group IV, these analyses were performed once. Liver and renal functions were also eveluated in group I-III. Serum immunoglobulin levels were analyzed in group 3. Skin tests with the suspected drug were applied in cases in group I and III according to the guidelines. In group II, skin tests, drug provocation tests, and viral serology were performed if needed.

Results

Absolute numbers of peripheral blood lymphocytes ans sFasL levels in initial samples of cases in 4 groups are summarized in Table 1.

Group 1Group 2Group 3Group 4
sFasL (ng/ml)Mean±SD0.20±0.140.24±0.160.22±0.160.19±0.21
Median0.270.200.180.10
CD3+/CD4+ cells*Mean±SD1508±12301761±824918±5521240±347
Median102616047411212
CD3+/CD8+ cells*Mean±SD1735±1839888±463509±355723±252
Median1376910407624
CD19+ cells*Mean±SD622±3221049±659195±181535±286
Median630834132489
CD3)/CD16+/CD56+(NK cells)*Mean±SD151-980264-300920-487103-1241
Median250±238181±11194±34253±235

*Counts, cells/ml

B cell counts were low in group III when compared to group I and IV. CD4+cells, CD19+cells and NK cells were low in group III when compared to group II. There were no significant differences in sFasL levels between the groups.

Conclusions

In our study, sFasL levels were not found to be useful to discriminate viral exanthemas from drug rashes. Additionally, the results were not found to be different on repeated evaluations. The only significant difference between drug induced MPRs and DRESS was B cell counts. The low numbers of B cells in DRESS within the first 2 days of the symptoms might be a useful predictor of DRESS development.